Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy is an effective low-density lipoprotein cholesterol (LDL-C) lowering option for patients with the highest risk of cardiovascular disease (CVD) events and high LDL-C despite the use of statin therapy, according to a recent review. Clinical trials include were from January 2012 to March 2018. Researchers found:
- All trials evaluating evolocumab and alirocumab demonstrated significant LDL-C lowering vs comparators.
- 2 trials revealed a decrease in the major adverse cardiovascular events (MACE) end point with PCSK9 inhibitor use.
- No significant safety concerns apart from injection site reactions were noted.
Patel RS, Scopelliti EM, Olugbile O. The role of PCSK9 inhibitors in the treatment of hypercholesterolemia. [Published online ahead of print April 1, 2018]. Ann Pharmacother. doi:10.1177/1060028018771670.
This Week's Must Reads
Detection & Management of Resistant Hypertension, Hypertension; ePub 2018 Sep 13; Carey, et al
Does Aspirin Prevent CV Events in Older Adults?, N Engl J Med; ePub 2018 Sep 16; McNeil, et al
Timing of ICD Placement From Last Hospitalization for HF, Circulation; ePub 2018 Sep 13; Ambrosy, et al
FFR and Quality of Life After PCI, Circulation; ePub 2018 Sep 18; Nishi, et al
VTE risk for continuous cycle oral contraceptives, Li J et al. JAMA Intern Med. 2018 Oct 1. doi:10.1001/jamainternmed.2018.4251
Must Reads in Hypercholesterolemia
Racial Differences in Statin Use, JAMA Cardiol; ePub 2018 Jun 13; Nanna, et al
LLT Use in Patients with Elevated LDL-C, Circ Cardiovasc Qual Outcomes; ePub 2018 May 10; Virani, et al
Evolocumab in Differing Patient Populations , J Pharmacokinet Pharmacodyn; ePub 2018 May 7; Kuchimanchi, et al
LDL-C Targets in Elderly Statin Users After ACS, J Am Heart Assoc; ePub 2018 May 12; Alter, et al
Patient Perspectives on Statin Therapy, Clin Cardiol; ePub 2018 May 10; Brinton